CJC-1295 (No DAC) Spray

Research-Documented Benefits

• Extended GH Release — Modified GRF(1-29) with amino acid substitutions at positions 2, 8, 15, and 27 provides improved resistance to enzymatic degradation while promoting pulsatile GH secretion.
• IGF-1 Elevation — Research demonstrates sustained increases in IGF-1 levels, supporting anabolic processes including tissue repair and protein synthesis.
• Preserved Feedback Mechanisms — Unlike exogenous GH, CJC-1295 (no DAC) maintains natural somatostatin-mediated negative feedback, preventing supraphysiological GH spikes.
• Body Composition — Preclinical studies indicate favorable changes in lean mass to fat mass ratios with chronic administration.
• Synergistic Potential — Research frequently pairs CJC-1295 with GHRP-class peptides (e.g., Ipamorelin) to amplify GH release through complementary receptor pathways.

Mechanism of Action

CJC-1295 (no DAC) is a modified form of GRF(1-29) with four amino acid substitutions (Ala2→D-Ala, Asn8→Gln, Ala15→Ala, Met27→Leu) that confer resistance to DPP-IV enzymatic degradation.

Primary Pathways

• GHRH Receptor Agonism — Binds the GHRH receptor on anterior pituitary somatotrophs with affinity comparable to native GHRH, but with a significantly extended half-life (~30 minutes vs. ~7 minutes for native GRF).
• Enhanced Stability — The D-Ala2 substitution blocks DPP-IV cleavage at the N-terminus, while Gln8 and Leu27 substitutions prevent asparagine rearrangement and methionine oxidation, respectively.
• Pulsatile Secretion — Promotes GH release in a pulsatile fashion that aligns with the body's natural ultradian rhythm, maintaining negative feedback through somatostatin.
• Synergy with GHRPs — CJC-1295 and GHRP-class peptides (such as ipamorelin) act on distinct receptor systems (GHRH-R vs. GHS-R1a), producing synergistic, amplified GH release when combined.

CJC-1295 without DAC provides a practical research tool for studying GHRH-axis physiology, offering improved stability without the prolonged, non-pulsatile GH elevation seen with DAC-conjugated versions.

Research Protocol Guidelines

All protocols described are for in vitro and in vivo research purposes only. Not for human use.

Reconstitution

Reconstitute lyophilized CJC-1295 (no DAC) with bacteriostatic water. For a 2 mg vial, adding 2 mL yields 1 mg/mL. Allow to dissolve gently without agitation.

Research Dosing (Preclinical Literature)

• Standard research dose: 1-2 mcg/kg subcutaneously, 1-3 times daily, typically coordinated with GHRP co-administration
• Saturation dose studies: 100 mcg per administration, representing the approximate saturation dose per pulse in GH-axis research
• Combination protocols: Commonly paired with ipamorelin at equimolar doses for synergistic GH release studies

Storage

Store lyophilized form at -20°C. Reconstituted solution at 2-8°C, use within 21 days. CJC-1295 (no DAC) is more stable than native GRF(1-29) but should still be protected from heat and light.

Safety & Handling Information

For research use only. Not intended for human or veterinary diagnostic or therapeutic use.

Storage Requirements

• Lyophilized: -20°C, desiccated, protected from light
• Reconstituted: 2-8°C, use within 21 days

Preclinical Safety Profile

CJC-1295 (no DAC) has been evaluated in Phase I and II clinical studies with an acceptable safety profile. The most common findings include injection site reactions and transient flushing.

Known Considerations

• Same neoplasia considerations as sermorelin—GH/IGF-1 axis stimulation warrants caution in tumor-bearing models
• Water retention may occur with sustained GH elevation in chronic studies
• Distinguish from CJC-1295 with DAC, which produces non-pulsatile, sustained GH elevation with different safety considerations

Handling

Standard laboratory PPE. Handle under aseptic conditions.

Frequently Asked Questions